LIVERMORE, Calif. & BOSTON, Mass.–(BUSINESS WIRE)–A partnership between Sandia National Laboratories and the Boston firm BioBright LLC to improve the security of synthetic biology equipment has become more relevant after the United States and others issued warnings that hackers were using the COVID-19 pandemic to increase their activities.
“In the past decade, genomics and synthetic biology have grown from principally academic pursuits to a major industry,” said computational biology manager Corey Hudson. “This shift paves the way toward rapid production of small molecules on demand, precision healthcare and advanced materials.”
Sandia and BioBright are working to develop better security for this new commercial field. Right now, large amounts of sensitive data about patients’ health and pharmaceutical information are being handled with security models developed two decades ago for academic needs and not industrial risks, Hudson said.
Many of the facilities responsible for ushering in this growth in synthetic biology scaled up from these academic models. This has meant that the digital environment responsible for automating these facilities has not grown with the same sophistication. According to Hudson, the situation potentially leaves open the risk of data theft or targeted attack by hackers to interrupt production of vaccines and therapeutics or the manufacture of controlled, pathogenic or toxic materials.
Charles Fracchia, BioBright CEO, said: “Modern synthetic biology and pharmaceutical workflows rely on digital tools. Instruments and software that were designed before security was such an important consideration.”
The risk associated with using dated security measures for a modern, automated process is rising in light of current events. On May 5, the Department of Homeland Security and the Cybersecurity, Infrastructure Security Agency and the United Kingdom’s National Cyber Security Centre issued a joint alert warning that malicious hackers were exploiting the COVID-19 pandemic as part of their attacks.
Earlier work by Hudson and his team focused on identifying, reporting and mitigating vulnerabilities in genomics and genomic operations within synthetic biology.
“You have a genetic sequencer that is producing terabytes of data,” Hudson said. “Those data are being transferred, through a series of software, until you identify the genetic variants. The clinical decisions are made from those results.”
Hudson and his team are collaborating with Fracchia’s team at BioBright, a company that provides secure data collection and analysis to biotech and pharmaceutical companies. They are working to help better secure synthetic biology operations and genomic data across industry, government and academia, protecting America’s bioeconomy and digital infrastructure. Using Emulytics, a research initiative developed at Sandia for evaluating realistic threats against critical systems, the teams are developing countermeasures to the risks.
“We can examine the data and see how to make the entire system safer and more secure,” Hudson said.
The initial work done by Hudson his team was funded through Sandia’s Laboratory Directed Research and Development program. The collaboration with BioBright is funded by the Defense Advanced Research Projects Agency through the Safe Genes project.
ENDS
About BioBright LLC www.biobright.com
BioBright’s mission is to revolutionize the way biological research is done by building tools that augment the scientist.
Initially funded by DARPA, the Company’s deep experience in biomedical research gives it a unique perspective on how to make research more reproducible by giving scientists unprecedented capabilities without burdening them. BioBright’s team comes from many of the leading laboratories including MIT, Harvard, Cornell, IBM and Ginkgo Bioworks.
BioBright is now working with some of the most impactful groups and companies to propel biomedical research into the digital age.
BioBright was acquired by Dotmatics Ltd. in June 2020.
Contacts
Sarah Jeffery
Zyme Communications
E: sarah.jeffery@zymecommunications.com
T: +1 857 366 5001